Atara Biotherapeutics (ATRA) EPS (Basic) Growth (3y) (2016 - 2026)
Analysis
Atara Biotherapeutics (ATRA) EPS (Basic) Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.24 Bn | 9.40 Bn | 112.79 Mn | 51.67% |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.67 Bn | 3.37 Bn | 55.72 Mn | 39.50% |
| 4 | Legend Biotech | 3.55 Bn | 2.59 Bn | 251.50 Mn | 32.71% |
| 5 | uniQure | 2.96 Bn | 2.96 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | - |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 44.39% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 34.14% |
| 10 | Atara Biotherapeutics | 148.53 Mn | 131.97 Mn | 439,000.00 | 73.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 73.31% |
| Mar 31, 2026 | 74.61% |
| Dec 31, 2025 | 64.55% |
| Sep 30, 2025 | 75.09% |
| Jun 30, 2025 | -64.95% |
| Mar 31, 2025 | 29.30% |
| Dec 31, 2024 | 59.21% |
| Sep 30, 2024 | 49.37% |
| Jun 30, 2024 | 48.52% |
| Mar 31, 2024 | 35.87% |
| Dec 31, 2023 | 19.56% |
| Sep 30, 2023 | 10.53% |
| Jun 30, 2023 | 15.95% |
| Mar 31, 2023 | 16.17% |
| Dec 31, 2022 | 21.81% |
| Sep 30, 2022 | 14.40% |
| Jun 30, 2022 | 28.33% |
| Mar 31, 2022 | 15.77% |
| Dec 31, 2021 | 18.23% |
| Sep 30, 2021 | 11.05% |